3,5-Disubstituted Pyrrolo[2,3-b]pyridine Analogs as SGK1 Inhibitors
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Serum- and glucocorticoid-regulated kinase 1 (SGK1) is considered a potential therapeutic target for cancer as its overexpression leads to uncontrolled cell proliferation and tumor formation. This study focuses on the structural modifications of SGK1 inhibitors, particularly 1H-pyrrolo[2,3-b]pyridine analogs, in which the carboxyl group is expected to interact with the ε-amino group of lysine at the SGK1 catalytic site. We investigated alternative functional groups to replace the carboxyl group and found that, while most substitutions reduced the inhibitory activity, the hydroxycarbamoyl group enhanced it. Additionally, the positions of these substituents are crucial, with para-substituents generally showing higher activity than meta-substituents. Interestingly, typical hydrogen bond acceptors did not improve activity, suggesting that hydrogen bonding may not be the primary interaction between the carboxyl group and lysine. Docking studies have provided further insights into binding interactions, enhancing our understanding of the molecular determinants essential for SGK1 inhibition.
Abstract
Serum- and glucocorticoid-regulated kinase 1 (SGK1) is considered a potential therapeutic target for cancer as its overexpression leads to uncontrolled cell proliferation and tumor formation. This study focuses on the structural modifications of SGK1 inhibitors, particularly 1H-pyrrolo[2,3-b]pyridine analogs, in which the carboxyl group is expected to interact with the ε-amino group of lysine at the SGK1 catalytic site. We investigated alternative functional groups to replace the carboxyl group and found that, while most substitutions reduced the inhibitory activity, the hydroxycarbamoyl group enhanced it. Additionally, the positions of these substituents are crucial, with para-substituents generally showing higher activity than meta-substituents. Interestingly, typical hydrogen bond acceptors did not improve activity, suggesting that hydrogen bonding may not be the primary interaction between the carboxyl group and lysine. Docking studies have provided further insights into binding interactions, enhancing our understanding of the molecular determinants essential for SGK1 inhibition.
참고문헌 (16)
- Bray F, "Global cancer statistics 2022 : GLOBOCAN estim-ates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 74, pp.229~263 (2024)
- Roskoski R, Jr., "Properties of FDA-approved small molecule protein kinase inhibitors : a 2024 update", Pharmacol Res, 200, pp.107059~ (2024)
- Riegel K, "Recent advances in targeting protein kinases and pseudokinases in cancer biology", Front Cell Dev Biol, 10, pp.942500~ (2022)
- Webster MK, "Characterization of sgk, a novel member of the serine", threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum, 1993, pp.13, 2031~2040
- Sang Y, "SGK1 in human cancer : emerging roles and mechanisms", Front Oncol, 10 (2021)
- Liang X, "Therapeutic inhibition of SGK1 suppresses colorectal cancer", Exp Mol Med, 49, pp.e399~ (2017)
- Jang H, "Serum and glucocorticoid-regulated ki-nase 1 : Structure, biological functions, and its inhibitors", Front Pharmacol, 13, pp.1036844~ (2022)
- Kim J, "Identification and kine-tic characterization of serum-and glucocorticoid-regulated kinase inhibitors using a fluorescence polarization-based assay", SLAS Discov, 26, pp.655~662 (2021)
- Trott O, "AutoDock Vina : improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading", J Comput Chem, 31, pp.455~461 (2010)
- Hammond M, "Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1(SGK1)inhibitors", Bioorg Med Chem Lett, 19, pp.4441~4445 (2009)
- Sherk AB, "Development of a small-molecule serum-and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic", Cancer Res, 68, pp.7475~7783 (2008)
- Zhao Q, "Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes", J Am Chem Soc, 139, pp.680~685 (2017)
- Champagne PA, "Organic fluorine as a hydrogen-bond acceptor : recent examples and applications", Synthesis, 47, pp.306~322 (2015)
- Esterhuysen C, "Trifluoromethyl : an amphiphilic noncovalent bonding partner", Chemphyschem, 18, pp.772~784 (2017)
- Adsmond DA, "Hydrogen bonding in sulfonamides", J Pharm Sci, 90, pp.2058~2077 (2001)
- Whyte GF, "Molecular recognition with boronic acids-applications in chemical biology", J Chem Biol, 6, pp.161~174 (2013)